| 1 | Self-curling electroconductive nerve dressing for enhancing peripheral nerve regeneration in diabetic rats显示文摘Conductive scaffolds have been shown to exert a therapeutic effect on patients suffering from peripheral nerve injuries(PNIs).However,conventional conductive conduits are made of rigid structures and have limited applications for impaired diabetic patients due to their mechanical mismatch with neural tissues and poor plasticity.We propose the development of biocompatible electroconductive hydrogels(ECHs)that are identical to a surgical dressing in this study.Based on excellent adhesive and self-healing properties,the thin film-like dressing can be easily attached to the injured nerve fibers,automatically warps a tubular structure without requiring any invasive techniques.The ECH offers an intimate and stable electrical bridge coupling with the electrogenic nerve tissues.The in vitro experiments indicated that the ECH promoted the migration and adhesion of the Schwann cells.Furthermore,the ECH facilitated axonal regeneration and remyelination in vitro and in vivo through the MEK/ERK pathway,thus preventing muscle denervation atrophy while retaining functional recovery.The results of this study are likely to facilitate the development of non-invasive treatment techniques for PNIs in diabetic patients utilizing electroconductive hydrogels. | Can Liu Lei Fan Zhenming Tian Huiquan Wen Lei Zhou Pengfei Guan Yian Luo Chuncheung Chan Guoxin Tan Chengyun Ning Limin Rong Bin Liu | 2021 | Bioactive Materials2021，6，11： | 1 |
| 3 | Candidate therapeutic agents in a newly established triple wild-typemucosalmelanoma cell line显示文摘Background:Mucosalmelanoma has characteristically distinct genetic features and typically poor prognosis.The lack of representativemucosal melanoma models,especially cell lines,has hindered translational research on this melanoma subtype.In this study,we aimed to establish and provide the biological properties,genomic features and the pharmacological profiles of a mucosal melanoma cell line that would contribute to the understanding and treatment optimization of molecularly-defined mucosal melanoma subtype.Methods:The sample was collected from a 67-year-old mucosal melanoma patient and processed into pieces for the establishment of cell line and patientderived xenograft(PDX)model.The proliferation and tumorigenic property of cancer cells from different passageswere evaluated,andwhole-genome sequencing(WGS)was performed on the original tumor,PDX,established cell line,and the matched blood to confirm the establishment and define the genomic features of this cell line.AmpliconArchitect was conducted to depict the architecture of amplified regions detected by WGS.High-throughput drug screening(HTDS)assay including a total of 103 therapeutic agents was implemented on the established cell line,and selected candidate agents were validated in the corresponding PDX model.Results:A mucosal melanoma cell line,MM9H-1,was established which exhibited robust proliferation and tumorigenicity after more than 100 serial passages.Genomic analysis of MM9H-1,corresponding PDX,and the original tumor showed genetic fidelity across genomes,and MM9H-1 was defined as a triple wild-type(TWT)melanoma subtype lacking well-characterized“driver mutations”.Instead,the amplification of several oncogenes,telomerase reverse transcriptase(TERT),v-Rafmurine sarcoma viral oncogene homolog B1(BRAF),melanocyte Inducing transcription factor(MITF)and INO80 complex ATPase subunit(INO80),via large-scale genomic rearrangement potentially contributed to oncogenesis of MM9H-1.Moreover,HTDS identified proteasome inhibitors,especially bortezomib,as promising therapeutic candidates for MM9H-1,which was verified in the corresponding PDX model in vivo.Conclusions:We established and characterized a new mucosal melanoma cell line,MM9H-1,and defined this cell line as a TWT melanoma subtype lacking well-characterized“driver mutations”.The MM9H-1 cell line could be adopted as a unique model for the preclinical investigation of mucosal melanoma. | Chaoji Shi Ziyue Gu Shengming Xu Houyu Ju Yunteng Wu Yong Han Jiayi Li Chuwen Li Jing Wu Lizhen Wang Jiang Li Guoyu Zhou Weimin Ye Guoxin Ren Zhiyuan Zhang Rong Zhou | 2022 | Cancer Communications2022，42，7： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员